Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of Actos, with franchise sales reaching nearly $6 billion by 2019. Pipeline candidates will make up 30% of sales in 2019, with once-weekly GLP-1 agonists and new long-acting insulin analogs meeting success.
Reasons to Purchase
* Quantify the future size of the antidiabetics market from 2010-2019 and identify opportunities for new products
* Examine the future performance of leading antidiabetic brands and the growth of generics and insulin biosimilars
* Understand the barriers to uptake for novel antidiabetic agents
N/A
Other selected research from the 'Metabolic disorders' category:
Pipeline Insight: Non-insulin Antidiabetics - Three New Classes Compete for Market Control
Despite the presence of well tried and liked compounds for the treatment of diabetes, such as insulin, metformin and sulfonylureas and the recent introduction of new classes such as TZDs, AGIs and PGRs, there are still important unmet needs in the treatment of diabetes. As a result, a great surge of activity towards the discovery and development of new agents has been recently noted. Learn More
Antidiabetics in Australia Market Forecast
Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth... Learn More